Navigation Links
New Device Treats Common Heart Rhythm Disorder
Date:3/28/2009

It could replace anti-clotting drug warfarin for many patients, researchers say,,,,

SATURDAY, March 28 (HealthDay News) -- An implanted device may soon replace the anti-clotting drug warfarin as the first line of treatment for many people with atrial fibrillation, a new study suggests.

People with atrial fibrillation have a sixfold increased risk of stroke, the researchers noted, and typically need to take warfarin for the rest of their lives. Atrial fibrillation is a common heart rhythm problem that causes the upper chamber of the heart to beat irregularly.

"One in four people over 50 will develop atrial fibrillation," lead researcher Dr. David R. Holmes Jr., the Scripps Professor of Medicine at the Mayo Graduate School of Medicine, said during a morning teleconference at the American College of Cardiology annual meeting Saturday in Orlando, Fla.

About 3 million people in the United States have atrial fibrillation, and 16 million Americans will have the condition by 2050, Holmes said. Stroke is the most serious complication related to atrial fibrillation, he noted.

"We know that in those patients with atrial fibrillation that the clot that causes that stroke comes from a certain area of the heart called the left atrial appendage," Holmes said, explaining that the appendage is a muscular pouch connected to the left atrium. "The device isolates the left atrial appendage."

To implant the device, an interventional cardiologist uses a catheter inserted in a leg vein to guide the device into the heart; the device travels through the heart's right chamber and is deposited into the left atrium through a puncture hole between the two chambers of the heart, the researchers explained.

Current treatment with warfarin is effective in preventing strokes caused by clots associated with atrial fibrillation, but its use needs to be monitored monthly to assure patients are receiving the safest and most effective dose because it can cause serious bleeding if given in doses that are too high, Holmes noted.

In the Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial, researchers compared treatment with warfarin to a fabric-covered, expandable cage called the WATCHMAN. The device blocks blood clots that typically form in the heart's left atrial appendage. The 707 patients were randomly assigned to one of the two treatments.

"Efficacy was dramatically better with the device, and stopping the warfarin," Holmes said.

The researchers found that patients with the WATCHMAN had a 32 percent lower risk of stroke and cardiovascular death compared with warfarin therapy. This was especially true for hemorrhagic stroke, which causes bleeding in the brain and is usually fatal, Holmes noted.

In addition, there were fewer complications with the device, once it was implanted, compared to warfarin. Most complications with the device occurred when placing it in the heart, but these complications now occur in only 1 percent of patients, Holmes noted.

The researchers concluded that the device is an effective alternative to warfarin for preventing stroke in patients with atrial fibrillation, particularly those at the highest risk of stroke.

"A strategy like this can be used in patients with non-valvular atrial fibrillation to prevent stroke, and get them off warfarin," Holmes said.

Dr. Gregg C. Fonarow, professor of cardiology at the University of California, Los Angeles, thinks this device will benefit many patients with atrial fibrillation.

"The major risk of atrial fibrillation is blood clots forming in the heart, and then breaking loose to cause stroke. Most of these blood clots form in the appendage of the left atrium," Fonarow said.

The only effective treatment until now was lifelong use of warfarin. Researchers have been searching for alternative therapies to warfarin to protect patients with atrial fibrillation from stroke without success for decades, Fonarow noted.

"The findings from this clinical trial are very impressive," Fonarow said. "Although there were some procedure-related complications, treatment with this novel device will be very attractive and provide patients with atrial fibrillation effective, long-term protection from stroke and systemic embolization without the bleeding risks associated with warfarin."

More information

For more information on atrial fibrillation, visit the American Heart Association.



SOURCES: Gregg C. Fonarow, M.D., professor, cardiology, University of California, Los Angeles; March 28, 2009, teleconference with: David R. Holmes, Jr., M.D., Scripps Professor of Medicine, Mayo Graduate School of Medicine, Rochester, Minn.


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New BSI CE-Onsite Facilitates CE Marking Reviews for Device Manufacturers
2. Mayo study shows simple finger device may help predict future heart events, such as heart attack
3. Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack
4. IH Systems Enters the Middle Eastern Medical Device Market
5. Chubb Named Preferred Insurance Provider for Medical Device Manufacturers
6. New Cardiovascular and Orthopaedic Content Pushes Materials for Medical Devices Database to Milestone
7. Scientists trial device to treat chemotherapy-related nausea
8. Unique nerve-stimulation device proves effective against epilepsy
9. Materials for Medical Devices Database Reaches Milestone
10. Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan
11. HemAway(R) Launches FDA-Cleared Painless Hemorrhoid Treatment Device
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Device Treats Common Heart Rhythm Disorder
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
Breaking Medicine Technology: